China's Next-Generation Cell Therapy Leaders: Innovation, Investment, and Strategic Collaboration
Among China's next-generation innovative drugs, cell therapy isOne of the fields most likely to propel China’s innovative drugs to the global forefront.
The number of clinical trials on cell therapies conducted in China has exceeded 500.It ranks first in China in terms of the number of innovative drug R&D projects, while also accounting for more than half of global cell therapies.Meanwhile, Legend Biotech’s BCMA-targeted CAR-T therapy received FDA approval for market launch.LetChina Takes the Lead in Global New Drug Development for the First Time。
China’s Cell Therapies See Unprecedented Growth.The cell therapy industry is also experiencing a surge of activity, with changes occurring across all fronts—technological innovation, investment and financing, and commercial partnerships—much like the flapping of butterfly wings stirring up waves across the Pacific:
Capital Aspects，The booming development of the cell therapy industry continues to attract substantial capital inflows,Even in the first quarter of 2022, amid a sharp correction in the secondary capital markets and widespread talk of a “capital winter,” investment enthusiasm in the cell therapy sector remained robust.
However, the direction of investment has undergone substantial changes.CAR-T therapies mired in cutthroat competition are likely to face a cold reception, while novel cell therapies such as CAR-NK, TIL, and TCR-T, along with companies integrating cutting-edge biotechnologies, have become the new favorites of capital.
Technical Aspects, In the face of the challenges and limitations of existing autologous CAR-T therapies, scientists are venturing into the field of novel cell therapies,Amid the interstices of iterative advancements in cell therapy, leading enterprises in the new generation of cell therapies are emerging.
IASO Biotherapeutics, a Cell Therapy Company in the First Tier, while maintaining its leading edge in hematologic malignancy R&D, it continues to exert strong efforts in solid tumors and universal cell therapies;Xingyiang IPS-CAR-NK, Tiankeya TCR-TAs emerging cell therapy companies garner significant attention from the industry, enterprises applying new technologies such as synthetic biology and chemistry to cell therapy continue to emerge; in the CDMO sector,PuXin Biologics is a leading CDMO specializing in cell-based therapeutics,It is also one of the few companies in China with service capabilities covering the full-process process development, IND filing, registration clinical trials, and commercial production of immune cell products such as CAR-T, TCR-T, and CAR-NK, as well as stem cell products.
Collaboration: In recent years, the number of collaborative developments and mergers and acquisitions in the field of cell therapy has increased significantly.According to statistics, there were 24 collaborative development projects in cell and gene therapy in 2020 alone, with a total transaction value of $11.2 billion. From 2021 to early this year, multiple domestic and international collaborations in the cell therapy field have been successively reached.
The case of Legend Biotech and Johnson & Johnson joining forces to propel the U.S. launch of their product, ciltacabtagene autoleucel, demonstrates—If cell therapy biotech companies can seize the opportunity to collaborate withStrategic alliances between major pharmaceutical companies will undoubtedly significantly accelerate the development and commercialization of cell therapy drugs.
China’s innovative drug sector is advancing at a rapid pace, with the landscape transforming significantly every five years.Following the respective approvals and market launches of the autologous CAR-T therapies from Fosun Kite, JW Therapeutics, and Legend Biotech in domestic and international markets, China’s cell therapy industry has entered its next stage of development.Leading next-generation cell therapy companies are on the rise, where technological innovation, fundraising capabilities, and business collaboration prowess are all indispensable.
From 19:00 to 20:30 on April 23, Qingsong Club’s online live broadcast program “Qingsong Bio Friends’ Stories“Leading Companies in Next-Generation Cell Therapy,” featuring an online “High-Level Dialogue” with Zheng Biao, Chief Scientific Officer of Caribou Biosciences; Zhu Yi, CEO of Puxin Biology; and Zhang Liang, Partner at Yuyin Medical Fund.
Some of the discussion topics are as follows:
As we entered 2022, what were the changing trends in investment within the cell therapy sector? Which areas attracted investment, and which ones no longer did?
How Should Entrepreneurs Respond to the Dramatic Changes in the Primary and Secondary Capital Markets?
In Which Field Will the Next Generation of Leading Cell Therapy Companies Emerge?
Can Emerging Therapies Such as CAR-NK, TIL, and TCR-T Overtake on the Bend? How Do They Surpass CAR-T Therapy?
What are the respective challenges behind the development of various novel cell therapies and emerging biotechnologies?
What New Collaboration Trends and Strategic Approaches Are Emerging in the Field of Cell Therapy?
Registration & Interaction
Lucky Draw Process
Registration process
Guest Introduction
Guests
Zheng Biao
Chief Scientific Officer, Xunlu Medical
Dr. Zheng Biao joined IASO Biotherapeutics in September 2020 and serves as Chief Scientific Officer (CSO).
Dr. Zheng Biao holds a Ph.D. in Clinical Medicine from the School of Medicine, Zhejiang University, and a Ph.D. in Immunology from the University of London. He previously served on the faculty at the University of Maryland School of Medicine and the Duke University Medical Center, and is currently a Tenured Professor in the Department of Pathology and Immunology at Baylor College of Medicine in the United States.
Dr. Zheng Bo possesses extensive research experience and a strong track record of achievements in the field of immunology. Prior to joining Legend Biotech, he led early-stage R&D for immune-mediated diseases at GlaxoSmithKline and served as Global Vice President in the field of immunotherapy at Johnson & Johnson.
Dr. Yi Zhu
CEO of PuXin Bio
Co-founder of Jiangsu Puxin Biopharmaceutical Co., Ltd. Previously served as Chief Strategy Officer and Head of R&D Center, overseeing the company’s overall business layout, investment and M&A, and overseas operations. Holds a Ph.D. in Immunology from Duke University School of Medicine, an MBA from Fudan University, and a Bachelor’s degree in Genetics from Fudan University. Possesses over 20 years of experience in drug R&D, clinical operations, financing and investment, and business development.
Previously served as the Head of Asia-Pacific for T-Cure Bioscience, a U.S.-based cell therapy company, where he facilitated and executed licensing collaborations and industrial implementation of several cell-based therapies between China and the United States. As a Clinical Operations Manager at Novartis, he led multiple early-phase clinical trials in the Asia-Pacific region and managed the European multicenter Phase III clinical trial for Gleevec. He has also held positions at the GSK Shanghai R&D Center, a prominent U.S. dollar-denominated venture capital fund, and Duke University Medical Center in the United States as an Assistant Researcher, as well as serving as a Principal Investigator (PI) at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine.
During my research career, my primary research interests have focused on the application of the PiggyBac transposon system in mammals, the establishment of B- and T-cell somatic hypermutation tumor models, and technologies for generating transgenic and gene-knockout mice. I have served as the principal investigator for several research and talent development grants awarded by the National Natural Science Foundation of China, the Shanghai Municipal Science and Technology Commission, and the Shanghai Municipal Education Commission.
Zhang Liang
Partner, OrbiMed Healthcare Fund
ZhangMr. Liang graduated from Zhejiang University and the University of Hong Kong.
With nearly 20 years of experience in the healthcare industry, having served at Pfizer and Bayer, with a focus on investments in biopharmaceuticals and their upstream and downstream sectors.
Event Registration
Sign up
